BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 28559118)

  • 1. Tumor regression grades, K-RAS mutational profile and c-MET in colorectal liver metastases.
    Lorenzon L; Ricca L; Pilozzi E; Lemoine A; Riggio V; Giudice MT; Mallel G; Fochetti F; Balducci G
    Pathol Res Pract; 2017 Aug; 213(8):1002-1009. PubMed ID: 28559118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection.
    Shoji H; Yamada Y; Taniguchi H; Nagashima K; Okita N; Takashima A; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y
    Cancer Sci; 2014 Aug; 105(8):1002-7. PubMed ID: 24863535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
    Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S
    J BUON; 2013; 18(1):116-23. PubMed ID: 23613396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations.
    Passot G; Chun YS; Kopetz SE; Overman MJ; Conrad C; Aloia TA; Vauthey JN
    Eur J Surg Oncol; 2016 Sep; 42(9):1378-84. PubMed ID: 27358198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
    Stremitzer S; Stift J; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
    Eur J Surg Oncol; 2015 Jul; 41(7):868-74. PubMed ID: 25865557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection.
    Passot G; Denbo JW; Yamashita S; Kopetz SE; Chun YS; Maru D; Overman MJ; Brudvik KW; Conrad C; Aloia TA; Vauthey JN
    Surgery; 2017 Feb; 161(2):332-340. PubMed ID: 27592215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
    Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
    Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MACC1 mRNA levels predict cancer recurrence after resection of colorectal cancer liver metastases.
    Isella C; Mellano A; Galimi F; Petti C; Capussotti L; De Simone M; Bertotti A; Medico E; Muratore A
    Ann Surg; 2013 Jun; 257(6):1089-95. PubMed ID: 23665971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases.
    Pietrantonio F; Mazzaferro V; Miceli R; Cotsoglou C; Melotti F; Fanetti G; Perrone F; Biondani P; Muscarà C; Di Bartolomeo M; Coppa J; Maggi C; Milione M; Tamborini E; de Braud F
    Med Oncol; 2015 Jul; 32(7):182. PubMed ID: 26003673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients.
    Vincenzi B; Cremolini C; Sartore-Bianchi A; Russo A; Mannavola F; Perrone G; Pantano F; Loupakis F; Rossini D; Ongaro E; Bonazzina E; Dell'Aquila E; Imperatori M; Zoccoli A; Bronte G; De Maglio G; Fontanini G; Natoli C; Falcone A; Santini D; Onetti-Muda A; Siena S; Tonini G; Aprile G
    Oncotarget; 2015 Oct; 6(31):31604-12. PubMed ID: 26384309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discrepancies between the K-ras mutational status of primary colorectal cancers and corresponding liver metastases are found in codon 13.
    Kawamata H; Yamashita K; Kojo K; Ushiku H; Ooki A; Watanabe M
    Genomics; 2015 Aug; 106(2):71-5. PubMed ID: 26026309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival.
    Olevian DC; Nikiforova MN; Chiosea S; Sun W; Bahary N; Kuan SF; Pai RK
    Hum Pathol; 2016 Mar; 49():124-34. PubMed ID: 26826419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma.
    Siyar Ekinci A; Demirci U; Cakmak Oksuzoglu B; Ozturk A; Esbah O; Ozatli T; Celik B; Budakoglu B; Turker I; Bal O; Turan N
    J BUON; 2015; 20(1):128-35. PubMed ID: 25778307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis.
    Kim HS; Heo JS; Lee J; Lee JY; Lee MY; Lim SH; Lee WY; Kim SH; Park YA; Cho YB; Yun SH; Kim ST; Park JO; Lim HY; Choi YS; Kwon WI; Kim HC; Park YS
    BMC Cancer; 2016 Feb; 16():120. PubMed ID: 26887348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status.
    Onitsuka T; Uramoto H; Ono K; Takenoyama M; Hanagiri T; Oyama T; Izumi H; Kohno K; Yasumoto K
    J Thorac Oncol; 2010 May; 5(5):591-6. PubMed ID: 20150826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases.
    Petrowsky H; Sturm I; Graubitz O; Kooby DA; Staib-Sebler E; Gog C; Köhne CH; Hillebrand T; Daniel PT; Fong Y; Lorenz M
    Eur J Surg Oncol; 2001 Feb; 27(1):80-7. PubMed ID: 11237496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphological aspects of the hepatic response to neoadjuvant therapy.
    Fernández-Aceñero MJ; Cortés-Guiral D; Muñoz LE; Martínez-Useros J; Pastor-Idoate C
    Pathol Res Pract; 2015 Sep; 211(9):665-70. PubMed ID: 26163186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior.
    Jang S; Hong M; Shin MK; Kim BC; Shin HS; Yu E; Hong SM; Kim J; Chun SM; Kim TI; Choi KC; Ko YW; Kim JW
    Hum Pathol; 2017 Jul; 65():21-30. PubMed ID: 28188750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colorectal liver metastases are more often super wild type. Toward treatment based on metastatic site genotyping?
    Allard MA; Saffroy R; de la Maisonneuve PB; Ricca L; Bosselut N; Hamelin J; Lecorche E; Bejarano MA; Innominato P; Sebagh M; Adam R; Morère JF; Lemoine A
    Target Oncol; 2015 Sep; 10(3):415-21. PubMed ID: 25420993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncosuppressor methylation: a possible key role in colon metastatic progression.
    Tommasi S; Pinto R; Petriella D; Pilato B; Lacalamita R; Santini D; Zito F; Colucci G; Paradiso A; Silvestris N
    J Cell Physiol; 2011 Jul; 226(7):1934-9. PubMed ID: 21506124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.